SNY Sanofi (SNY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001121404
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
307
13F, latest reported quarter
What the filings say about SNY
Congress, 1 year
No trades
Last one: sale, 2025-09-11
Sanofi insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Sanofi in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
307 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-27) · 3.1 days to cover · settled 2026-10-15
below 73% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SNY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns SNY: institutional holders (13F)
13F holdings, latest reported quarter
28,088,274 sh
$1.2B
10,702,527 sh
$456.6M
10,627,088 sh
$453.4M
8,008,572 sh
$341.6M
6,798,961 sh
$290.0M
Congress trades in SNY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-11 · disclosed 41 days later
$1,001 - $15,000
Bought 2025-08-04 · disclosed 39 days later
$1,001 - $15,000
Sold 2025-07-22 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Sold 2024-09-04 · disclosed 2 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SNY planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SNY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Integrity Dividend Summit Fund
$775.4K position · as of 2026-07-31
4.8%
VanEck Pharmaceutical ETF
$35.2M position · as of 2026-06-30
4.0%
Catalyst/MAP Global Equity Fund
$3.1M position · as of 2026-06-30
3.2%
Brandes International Equity Fund
$81.7M position · as of 2026-06-30
3.1%
Invesco International Dividend AchieversTM ETF
$28.7M position · as of 2026-07-31
3.1%
Polen International Dividend Income ETF
$6.0M position · as of 2026-07-31
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
402 registered trials, 151 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
71
Phase 1
11 active
82
Phase 2
33 active
100
Phase 3
49 active
37
Phase 4
10 active
82
Not applicable
35 active
30
Multi-phase
13 active
What changed recently
SAR447971 First-in-human Study
2026-10-28 · Completion moved 2028-02-16 → 2028-04-17
Phase 1
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib an
2026-10-27 · Completion moved 2027-01-08 → 2027-04-01
Phase 2
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib an
2026-10-27 · Recruiting → Active Not Recruiting
Phase 2
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Par
2026-10-24 · Not Yet Recruiting → Recruiting
Phase 1
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients
2026-10-24 · Completion moved 2026-12-25 → 2027-06-30
Not applicable
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib i
2026-10-23 · Active Not Recruiting → Terminated · Business decision
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 307 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SNY financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Gross profit | $33.7B | $31.1B | $29.0B | $28.7B |
| Net income | $7.9B | $5.6B | $5.4B | $8.5B |
SEC XBRL, fiscal years, as known on 2026-10-28
SNY Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SNY filings, in plain words
Have members of Congress traded SNY?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-09-11.
Read the full summary
Members of Congress have disclosed trades in SNY, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-09-11. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
